Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 See also  





2 References  














SER-601






Српски / srpski
Srpskohrvatski / српскохрватски
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


SER-601
Clinical data
Routes of
administration
Oral
Identifiers
  • N-(Adamant-1-yl)-1-pentyl-4-oxo-6-isopropyl-1,4-dihydroquinoline-3-carboxamide

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H38N2O2
Molar mass434.624 g·mol−1
3D model (JSmol)
  • CC(C)c5ccc(c1c5)n(CCCCC)cc(c1=O)C(=O)NC4(C2)CC(CC2C3)CC3C4

  • InChI=1S/C28H38N2O2/c1-4-5-6-9-30-17-24(26(31)23-13-22(18(2)3)7-8-25(23)30)27(32)29-28-14-19-10-20(15-28)12-21(11-19)16-28/h7-8,13,17-21H,4-6,9-12,14-16H2,1-3H3,(H,29,32) checkY

  • Key:KUMKLUDNETVLDS-UHFFFAOYSA-N checkY

 ☒NcheckY (what is this?)  (verify)

SER-601 (COR-167) is a drug which acts as a potent and selective cannabinoid CB2 receptor agonist, based on a quinolone-3-carboxylic acid core structure, with 190 times selectivity for CB2 over the related CB1 receptor. It has analgesic effects in animal studies, as well as neuroprotective effects,[1] but without a "cannabis high" due to its low affinity for CB1.[2] A number of related compounds are known, almost all of which have high selectivity for CB2.[3]

See also[edit]

References[edit]

  1. ^ Contartese A, Valoti M, Corelli F, Pasquini S, Mugnaini C, Pessina F, et al. (December 2012). "A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury". Pharmacological Research. 66 (6): 555–563. doi:10.1016/j.phrs.2012.08.003. PMID 23036353.
  • ^ Pasquini S, Botta L, Semeraro T, Mugnaini C, Ligresti A, Palazzo E, et al. (August 2008). "Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo". Journal of Medicinal Chemistry. 51 (16): 5075–5084. doi:10.1021/jm800552f. PMID 18680276.
  • ^ Pasquini S, Ligresti A, Mugnaini C, Semeraro T, Cicione L, De Rosa M, et al. (August 2010). "Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands". Journal of Medicinal Chemistry. 53 (16): 5915–5928. doi:10.1021/jm100123x. PMID 20718492.
  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=SER-601&oldid=1187276100"

    Categories: 
    Cannabinoids
    Adamantanes
    4-Quinolones
    Carboxamides
    Enones
    Cannabinoid stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugs missing an ATC code
    Drugs with no legal status
    Drugboxes which contain changes to verified fields
    All stub articles
     



    This page was last edited on 28 November 2023, at 07:07 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki